Key Program Features

  • First-in-class α9α10 nAChR antagonist
  • Non-opioid: non-addictive and non-tolerizing chronic pain therapy
  • Analgesic, anti-inflammatory and neuroprotective effects
  • Well tolerated with no observed toxicities in chronic studies

KCP-400 for Chronic Pain

Drug Development Phase: Pre-clinical

Chronic pain is one of the largest and most widely-acknowledged unmet medical needs in the world. Current therapies like opioids, anti-epileptics and NSAIDs can be minimally effective and have the potential to cause dependence, are susceptible to tolerance or have intolerable side effects. There are 259 million opioid prescriptions written every year and ~50 people die every day from prescription opioid overdose in the US1.

KCP-400 is a novel non-opioid therapy for the treatment of chronic pain. It is a highly potent α9α10 nAChR antagonist that has demonstrated robust analgesic, anti-inflammatory and neuroprotective effects across multiple animal chronic pain models. It offers the potential of a disease modifying therapy that slows the progression of chronic pain.

KCP-400’s drug target is not expressed in the central nervous system leading to a safer therapy with no centrally mediated toxicities. Unlike other chronic pain therapies, KCP-400 is non-addictive and non-tolerizing. It has a favorable toxicology profile with a broad therapeutic index in preclinical studies.

References:
1. CDC "Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin" 2015